Andrew Allen

Company: Gritstone bio, Inc.

Seminars:

Now It Gets Real- Clinical Data in Advanced Cancer Patients Treated With an Individualized Neoantigen Vaccine 9:30 am

Neoantigen-directed immunotherapy has been developed using high quality machine learning-enabled prediction of neoantigens plus viral vector-based delivery of select individualized neoantigens to patients with advanced solid tumors A phase 1/2 trial has been conducted in the US/Australia to assess safety, immunogenicity and efficacy of this approach Clinical data with up to a year of follow-up,…Read more

day: Day Two

Industry Leader’s Fireside Chat 11:00 am

An executive panel discussion from the C-level leaders of the field to set the scene on neoantigen based therapy development.Read more

day: Day Two